세계의 인간용 백신 보조제 시장 규모 : 유형별, 투여 경로별, 용도별, 지역별 범위 및 예측

Human Vaccine Adjuvants Market Size And Forecast

Human Vaccine Adjuvants Market size was valued at USD 1.59 Billion in 2024 and is projected to reach USD 4.5 Billion by 2032, growing at a CAGR of 12.1 % during the forecast period 2026-2032.

Global Human Vaccine Adjuvants Market Drivers

The market drivers for the Human Vaccine Adjuvants Market can be influenced by various factors. These may include:

• Growing Prevalence of Infectious illnesses: Vaccine demand is rising as infectious illnesses continue to pose serious risks to public health around the world. This is the reason why adjuvants for vaccinations are necessary to increase their effectiveness.
• Increasing Vaccine Development Investments: Following pandemics such as COVID-19, governments, private groups, and pharmaceutical firms are making significant investments in vaccine research and development. Adjuvants that can increase vaccine efficacy are in higher demand as a result of this increasing spending.
• Technological Developments: Immunology and technological breakthroughs have produced innovative adjuvants that can elicit more robust immune responses, increasing the market's demand for these goods.
• Growing Senior Population: As immune systems deteriorate with age, older people are more vulnerable to infectious diseases. Consequently, there is a growing emphasis on creating vaccinations against illnesses like shingles, pneumonia, and influenza, which need adjuvants to be more effective against older persons.
• Extending immunization Programs: To stop the spread of infectious illnesses, particularly in developing nations, governments and international organizations are putting in place broad immunization programs. As a result, there is a need for vaccine adjuvants to fund these initiatives.
• Growing Public Awareness of Preventive Healthcare: As public awareness of the value of vaccination in illness prevention rises, so does public acceptance of vaccines. Adjuvants that can boost immune responses and increase vaccine effectiveness are in high demand as a result.
• Increase in Pandemic Preparedness: COVID-19 and other recent pandemics have brought attention to the significance of being ready for newly developing infectious illnesses. Investments in adjuvant research and vaccine development have increased as a result, enabling quick reactions to potential outbreaks in the future.
• Regulatory Support: Regulatory bodies are expediting the approval procedures for adjuvanted vaccines as they become more aware of the value of adjuvants in vaccine development. This propels market expansion by incentivizing pharmaceutical companies to allocate resources on adjuvant research and development.

Global Human Vaccine Adjuvants Market Restraints

Several factors can act as restraints or challenges for the Human Vaccine Adjuvants Market. These may include:

• Regulatory Difficulties: Because adjuvants may affect the safety and effectiveness of vaccines, they are closely inspected by the government. It might take time and money to comply with regulatory criteria for approval, which prevents new businesses from entering the market.
• Safety Issues: Adjuvants that raise safety issues may not be used as much in vaccine formulations. Adjuvants have the potential to elicit negative reactions or localized discomfort at the injection site, which could make patients and healthcare providers hesitant.
• Cost Restrictions: Adjuvant development and production can be expensive, especially for unique or proprietary formulas. Expensive vaccinations may be produced at high costs, which could restrict availability for some patient populations or in environments with limited resources.
• Limited Adoption: It may be difficult for newly adjuvanted vaccinations to become widely accepted because traditional vaccines without adjuvants may already be well-established in the market. Patients and healthcare professionals could be hesitant to move to new products unless there is compelling proof of increased safety or efficacy.
• Intellectual Property Problems: Adjunctive technology' intellectual property rights may make it difficult for new competitors to enter the market. Patent conflicts, proprietary formulae, and licensing agreements can stifle market competition and innovation.
• Manufacturing Difficulties: Increasing the production of vaccines with adjuvants can be difficult and necessitate certain facilities and manufacturing techniques. Adjuvanted vaccine supply and cost may be impacted by manufacturing limitations such as capacity limitations or production delays.
• Public opinion and adoption: Adjuvants' adoption and uptake can be impacted by the public's opinion of them, which can be shaped by things like vaccine hesitancy or disinformation. For the adjuvant market to flourish, it is imperative that safety and efficacy issues are addressed through education and communication initiatives.
• Global Health Inequities: Market constraints for adjuvanted vaccines may be made worse by differences in the availability of healthcare and vaccinations among geographic or socioeconomic groups. For the market to grow, these disparities must be addressed by focused pricing tactics, harmonized regulations, and infrastructure spending.

Global Human Vaccine Adjuvants Market Segmentation Analysis

The Global Human Vaccine Adjuvants Market is Segmented on the basis of Type, Route of Administration, Application, and Geography.

Human Vaccine Adjuvants Market, By Type

• Aluminum Salts: Traditional adjuvants widely used in vaccines to enhance immune response and improve antigen persistence. Examples include aluminum hydroxide, aluminum phosphate, and aluminum potassium sulfate.
• Oil-based Adjuvants: Lipid-based formulations that promote antigen uptake and activation of immune cells. Examples include MF59 (squalene oil-in-water emulsion) and AS03 (squalene-based adjuvant system).
• Mineral Salts: Adjuvants composed of mineral salts such as calcium phosphate, calcium carbonate, and magnesium hydroxide, which enhance antigen presentation and stimulate immune response.
• Adjuvant Systems: Combination adjuvant formulations designed to elicit specific immune responses and enhance vaccine efficacy. Examples include AS04 (aluminum hydroxide with monophosphoryl lipid A) and AS01 (liposome-based adjuvant containing MPL and QS-21).

Human Vaccine Adjuvants Market, By Route of Administration

• Intramuscular (IM) Administration: Vaccines administered via injection into the muscle, commonly utilizing adjuvants to enhance immunogenicity and promote long-lasting immunity.
• Subcutaneous (SC) Administration: Vaccines injected under the skin, often incorporating adjuvants to improve antigen delivery and stimulate immune response.
• Intradermal (ID) Administration: Vaccines administered directly into the skin using a microneedle or other delivery device, with adjuvants facilitating antigen uptake by immune cells in the dermis.

Human Vaccine Adjuvants Market, By Application

• Infectious Diseases Vaccines: Adjuvants used in vaccines against infectious diseases such as influenza, hepatitis B, human papillomavirus (HPV), and meningococcal disease, aiming to induce protective immunity and prevent infection.
• Cancer Vaccines: Adjuvants incorporated into cancer vaccines to stimulate immune responses against tumor-specific antigens, potentially leading to tumor regression or prevention of cancer recurrence.
• Autoimmune Disease Vaccines: Adjuvants utilized in vaccines targeting autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and lupus, aiming to modulate immune responses and induce tolerance to self-antigens.

Human Vaccine Adjuvants Market, By Geographic

• North America: A significant market for human vaccine adjuvants, driven by high healthcare spending, extensive vaccination programs, and strong research and development activities in the pharmaceutical and biotechnology sectors.
• Europe: Europe has a robust market for vaccine adjuvants, supported by the presence of leading vaccine manufacturers, government initiatives to promote immunization, and growing demand for novel adjuvant technologies.
• Asia-Pacific: Emerging as a key market for human vaccine adjuvants, fueled by increasing awareness of preventive healthcare, rising incidence of infectious diseases, and expanding vaccine manufacturing capabilities in countries like China and India.
• Latin America, Middle East, and Africa: These regions are witnessing growing investments in healthcare infrastructure, vaccination campaigns, and disease prevention efforts, driving demand for human vaccine adjuvants to improve vaccine efficacy and public health outcomes.

Key Players

• The major players in the Human Vaccine Adjuvants Market are:
• GlaxoSmithKline plc
• Merck & Co Inc.
• Novartis AG
• AstraZeneca plc
• Bavarian Nordic
• Adjuvance Technologies Inc.
• Vaxine Pty Ltd.
• Dynavax Technologies Corporation

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HUMAN VACCINE ADJUVANTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL HUMAN VACCINE ADJUVANTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY TYPE

• 5.1 Overview
• 5.2 Aluminum Salts
• 5.3 Oil-based Adjuvants
• 5.4 Mineral Salts
• 5.5 Adjuvant Systems

6 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY APPLICATION

• 6.1 Infectious Diseases Vaccines
• 6.2 Cancer Vaccines
• 6.3 Autoimmune Disease Vaccines

7 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

• 7.1 Intramuscular (IM) Administration
• 7.2 Subcutaneous (SC) Administration
• 7.3 Intradermal (ID) Administration

8 GLOBAL HUMAN VACCINE ADJUVANTS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
• 8.6 Latin America
• 8.7 Middle East and Africa

9 GLOBAL HUMAN VACCINE ADJUVANTS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Serum Institute of India
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Brenntag Biosector
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 CSL Limited
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 SEPPIC
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Agenus, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Novavax, Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 SPI Pharma, Inc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Invivogen
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Avanti Polar Lipids
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 MVP Laboratories
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research